Market capitalization | €1.34b |
P/E (TTM) P/E ratio | 12.47 |
P/S ratio (TTM) P/S ratio | 2.60 |
Dividend yield | 3.60% |
Last dividend (FY24) | €0.16 |
Revenue growth (TTM) Revenue growth | 11.14% |
Revenue (TTM) Revenue | €515.51m |
EBIT (operating result TTM) EBIT | €106.10m |
EPS (TTM) EPS | €0.35 |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
5 Analysts have issued a Faes Farma SAReg forecast:
5 Analysts have issued a Faes Farma SAReg forecast:
Mar '25 |
+/-
%
|
||
Revenue | 516 516 |
11%
11%
|
|
Gross Profit | 342 342 |
11%
11%
|
|
EBITDA | 127 127 |
1%
1%
|
EBIT (Operating Income) EBIT | 106 106 |
0%
0%
|
Net Profit | 109 109 |
15%
15%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Faes Farma SA operates as a pharmaceutical company. It engages in manufacturing and sale of chemical and pharmaceutical products, as well as the acquisition, purchase, sale, investment, holding, administration, management, negotiation and leasing of companies, of transferable and immovable securities, patents, trademarks and registrations and social participations. The company was founded in 1933 and is headquartered in Leioa, Spain.
Head office | Spain |
CEO | Eduardo Cuadra |
Employees | 1,775 |
Founded | 1933 |
Website | faesfarma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.